Faculty
Ravi Vij.jpg

Ravi Vij, MD, MBA

Professor
Department of Medicine
Oncology Division
Bone Marrow Transplantation & Leukemia

Research Interests

  • Stem cell transplantation for hematologic malignancy
  • Multiple myeloma
  • Acute myeloid leukemia/myelodysplastic syndromes

Contact

  • 314-454-8304 (office)
  • 314-454-8323 (secretary)
  • 314-454-7551 (fax)
  • 11th Floor Mid-Campus Center (office)
  • Division of Oncology
    Campus Box 8007
    Washington University Medical School
    660 South Euclid Avenue
    St. Louis, MO 63110

Invited Reviews & Commentaries

  • ASCO 2014: hematologic malignancy highlights
    Vij R
    Oncology Times 2015
  • Targeted treatments for multiple myeloma: specific role of carfilzomib
    Sugumar D, Keller J, Vij R
    Pharmgenomics Pers Med 2015 Jan 20;8:23-33
  • Key myeloma takeaways from ASH 2014
    Vij R
    Oncology Times 2015;37(3):1,7-9
  • Best myeloma research 2014
    Vij R
    Oncology Times 2015;36(24):1,13-15
  • ASCO 2014: hematologic malignancy takeaways
    Vij R
    ASCO 2014 36(14):1,14-16
  • Best myeloma research 2013
    Vij R
    Oncology Times 2014;36(3)
  • Freedom from the infusion chair
    Vij R
    Value Based Care in Multiple Myeloma 2013 Oct
  • Haematological cancer: a step before the next leap?
    Vij R
    Nat Rev Clin Oncol 2013 Nov;10(11):610-2
  • Frontline therapy for transplant eligible and ineligible patients
    Vij R
    Considerations in Multiple Myeloma 2012 Oct;5(3)
  • Carfilzomib promising in relapsed and refractory multiple myeloma: expert insight
    Vij R
    Clinical Oncology 2012 Sep;7(9):20
  • Carfilzomib in multiple myeloma
    Vij R
    Clin Adv Hematol Oncol 2012 Sep;10(9):591-3
  • Evolution of definitions of response, progression-free survival and event-free survival in front-line studies of chronic myeloid leukemia
    Ansstas G, Vij R
    Leuk Lymphoma 2012 Jul;53(7):1273-81
  • Carfilzomib – a next-generation proteasome inhibitor for the treatment of relapsed and/or refractory multiple myeloma
    Siegel DS, Vij R, Niesvizky R
    US Oncology & Hematology - Touch Briefings, in press
  • Best of ASCO 2012: hematological malignancies - pasma cell dyscrasias, acute lymphoblastic leukemia, chronic myelogenous leukemia, & chronic lymphocytic leukemia
    Vij R
    Oncology Times 2012 Jul
  • Best myeloma research of 2011
    Vij R
    Oncology Times 2012 Feb;34(3):18
  • Key myeloma takeaways from ASH 2011
    Vij R
    Oncology Times 2012 Jan;34(2):22-5
  • How I treat patients with newly diagnosed multiple myeloma who are not eligible for clinical trials
    Vij R
    Oncology Times 2011 Nov;33(22):22,24-26
  • Treatment-related adverse events in patients with relapsed/refractory multiple myeloma
    Vij R
    Oncology 2011 Nov;25(2)
  • Clinical roundtable monograph. Emerging treatment options for relapsed and refractory multiple myeloma
    Siegel DS, Vij R, Jakubowiak AJ
    Clin Adv Hematol Oncol 2011 Apr;9(4):1-15
  • Conflicts of interest, authorship, and disclosures in industry-related scientific publications
    Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan D, Rosenblatt J, Jagannath S, Niesvizky R, Landau H, Chen-Kiang S, Siegel DS, Zimmerman T, Mehta J, Vesole D, Rosen S, Hofmeister C, Lacy M, Dispenzieri A, Borrello I, Hayman SR, Kumar S, Buadi F, Dingli D, Russell S, Melissa Alsina MA, Fernandez H, Roy V, Pereira D, Stadtmauer E, Vij R, Jakubowiak A, Lentzsch S, Song K, Trudel S, Chen C, Reece D, Stewart D, Singhal S, Comenzo R, Gertz MA, Greipp PR, Durie B, Barlogie B, Anderson K, Dalton W, Coleman M, Novis S, Kyle RA
    Mayo Clin Proc 2010 Feb;85(2):197-9; author reply 201-4
  • Molecular pathology of myeloproliferative neoplasms
    Klco JM, Vij R, Kreisel FH, Hassan A, Frater JL
    Am J Clin Pathol 2010 Apr;133(4):602-15
  • Clofarabine: a size that fits all, may not fit all
    Vij R
    Leuk Lymphoma 2009 Mar;50(3):309-10
  • Optimizing the dasatinib dose regimen in chronic phase chronic myeloid leukemia (CP CML): 100 mg once daily available for use
    Vij R
    Commun Oncol 2009;6:18–20
  • In defense of high dose chemotherapy for multiple myeloma
    Vij R
    American Journal of Hematology and Oncology 2007;6(3) suppl 3:17-19
  • Recent advances in stem cell transplantation
    Vij R
    Medicine Update (Anniversary Issue 2003)
  • WebEBM Clinical Practice Guidelines for Adult Myelodysplastic Syndrome
    Vij R, DiPersio J
    Feb 2002
  • WebEBM Clinical Practice Guidelines for Adult Chronic Lymphoid Leukemia
    Vij R, DiPersio J
    Feb 2002
  • WebEBM Clinical Practice Guidelines for Adult Chronic Myeloid Leukemia
    Vij R, DiPersio J
    Feb 2002
  • WebEBM Clinical Practice Guidelines for Adult Acute Lymphoblastic Leukemia
    Vij R, DiPersio J
    Feb 2002
  • WebEBM Clinical Practice Guidelines for Adult Acute Myeloid Leukemia
    Vij R, DiPersio J
    Feb 2002

Books

  • Contemporary Multiple Myeloma Management
    Vij R
    JayPee Brothers Medical Publishers, 2012

Book Chapters

  • Multiple myeloma and plasma cell dyscrasias
    Keller J, Vij R
    Washington Manual of Oncology, 3rd edition, Lippincott Williams & Wilkins Publishers, 2014 in press
  • Special topics in multiple myeloma (special populations, adverse effects and supportive therapy)
    Vij R
    Living Medical E-textbook. Projects in Knowledge, April 2013
  • Targeted treatment of multiple myeloma: proteasome inhibitors
    Sanfillipo K, Vij R
    Current and Emerging Therapeutics for Multiple Myeloma, Future Science Group E-Book, 2013
  • Plasma cell neoplasms
    Vij R, Ramsingh G
    Cancer: Principles and Practices of Oncology Review, 3rd Edition, Wolters Kluwer, Lippincott Williams & Wilkins 2011
  • Essential Cancer Pharmacology, The Prescriber's Guide
    Vij R
    Wolters Kluwer, Lippincott Williams & Wilkins 2009
  • Plasma cell neoplasms
    Vij R, Ramsingh G
    Cancer: Principles and Practices of Oncology Review, 2nd Edition (Wolters Kluwer, Lippincott Williams & Wilkins 2009)
  • Multiple myeloma and plasma cell dyscrasias
    Wildes T, Vij R
    Washington Manual of Oncology, 2nd edition (Lippincott Williams & Wilkins 2008:333-343)
  • Plasma cell neoplasms
    Vij R
    Cancer: Principles and Practices of Oncology Review, First Edition. (Lippincott Williams and Wilkins 2005)
  • Combination chemotherapy regimen: multiple myeloma
    Vij R
    Pocket Guide to Injectable Chemotherapeutic Agents, Fifth Edition (Midwest Book Publishing 2009)
  • Cytokines in allogeneic stem cell mobilization
    Vij R, DiPersio
    Allogeneic Stem Cell Transplantation Clinical Research and Practice (Humana Press 2003:159-168)
  • Multiple myeloma and plasma cell dyscrasias
    Read W, Vij R
    Washington Manual of Oncology (Lippincott Williams & Wilkins Publishers 2002:297-309)
  • Principles of high dose therapy and stem cell transplantation
    Vij R, Westervelt P, DiPersio J
    Washington Manual of Oncology (Lippincott Williams & Wilkins Publishers 2002:78-99)
  • The effects of multilineage cytokines on platelet recovery
    Vij R, DiPersio J
    Clinical Applications of Cytokines and Growth Factors (Kluwer Academic Publishers. 1999: 237-268)